Russia
The Russian market is the largest in Central and Eastern Europe and is also one of the fastest growing.
The market is fragmented and no one company dominates. State involvement in the market is limited and most expenditures on
drugs are made directly by individuals to pharmacists. At the end of 2007, Barr's largest selling product in Russia was Sumamed,
which retained a leading position despite more than 15 generic competitors.
In 2005, the government created the first federal healthcare program, known
as the "DLO," providing reimbursement for drugs on the DLO list. In November 2006, the government published a revised DLO list with
significant changes that have affected participating companies to differing degrees. In addition, the DLO budget was significantly
overspent in 2006, which has created large delays in payment to producers. As a result, the Company has decreased its participation
in the DLO market, and in 2007 nearly 95% of its sales in Russia were in the commercial market.
Barr believes that the Russian market offers significant growth potential because of the overall robust economy and the relatively untapped nature of the market.
As a result, the Company will continue to seek to expand
operations in this market.
Product Guide 
